We possess extensive manufacturing and R&D infrastructure for carrying out drug development on novel Biotech products, and to cater to the commercial production of our Biogeneric drugs. All our facilities, for Biogenerics and Biotech products, conform to cGMP guidelines for carrying out sterile fermentation operations. Our facilities are designed for the bacterial, mammalian and viral based production inherent in our product development and commercial production activities.
Apart from the existing infrastructure, we are in the process of acquiring another 10 acres of land on which a 60 Kl facility will be commissioned to expand our commercial production capabilities for biogeneric drugs, and another 12 Kl capacity is being added to the existing plant. We have also initiated plans to upgrade all our facilities to conform to US FDA and EMA guidelines.
Some of the facilities we currently have include: